FOLFIRINOX + RT for Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01591733
Recruitment Status : Active, not recruiting
First Posted : May 4, 2012
Last Update Posted : September 29, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Theodore Sunki Hong, Massachusetts General Hospital

Brief Summary:

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of a therapy to learn whether the therapy works in treating a specific cancer. "Investigational" means that the therapy is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if therapy is effective for treating different types of cancer. Proton beam radiation therapy is an FDA (U.S. Food and Drug Administration) approved radiation delivery system.

Proton beam radiation therapy is known to spare surrounding normal tissues from radiation as it delivers less radiation beyond the area of the target tissues. This may reduce side effects that patients would normally experience with standard (photon) radiation therapy, which tends to include more normal tissue along with tumor target tissue.

Researchers in the laboratory have discovered that there are pathways inside the cells that can lead to growth and survival of the tumor. The chemotherapy drugs FOLFIRINOX and capecitabine are targeted towards blocking the pathways that allow cancer cells to divide, and may result in the tumor shrinking in size.

In this research study, the investigators are looking to determine if proton beam radiation in combination with FOLFIRINOX and capecitabine is effective in controlling the growth of your cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: FOLFIRINOX Drug: Capecitabine Radiation: Short Course Radiation Procedure: Surgery Phase 2

Detailed Description:

For weeks 1-8, you will only be receiving FOLFIRINOX via IV infusion. The treatment plan will begin with four cycles (8 weeks) of FOLFIRINOX. Each cycle is 14 days long. You will receive FOLFIRINOX therapy on days 1, 2 and 3 of each of the four cycles. The FOLFIRINOX treatment is broken up into three different drugs. 5-FU will be administered over two hours on day one of each cycle, and then continuously with a pump for days 2 and 3. Oxaliplatin will be delivered by intravenous (infusion) over 120 minutes. Irinotecan will be given by IV for 90 minutes. All parts of this treatment will be received as an outpatient.

If after 4 cycles of FOLFIRINOX therapy, your tumor has not spread, you will receive a further 4 cycles of FOLFIRINOX. If after 8 total cycles of FOLFIRINOX your cancer is clearly resectable, you will proceed to phase 2 of treatment with capecitabine and radiation therapy.

You will take tablets of capecitabine by mouth for a total of 10 days (Monday through Friday) during the two weeks after your FOLFIRINOX treatment.

You will be given a drug diary for capecitabine which contains instructions on how to take the drug.

Short course radiation: You will receive proton radiation treatment for five days (Monday through Friday) after your FOLFIRINOX treatment, during the time of your capecitabine treatment, or photon radiation for ten days (Monday through Friday for two weeks). You will also be assessed at least once during this treatment course for any side effects you may be experiencing.

You will receive study radiation treatment as an outpatient at the Francis H. Burr Proton Center or the Clark Center for Radiation Oncology at the Massachusetts General Hospital Surgery is expected to occur approximately one to four weeks after completion of capecitabine therapy.

After your surgery, you may receive additional chemotherapy at the discretion of your treating physician and be followed as per standard of care.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer
Actual Study Start Date : May 2012
Actual Primary Completion Date : March 2017
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treatment Arm
All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
Up to Eight-14 day cycles
Other Names:
  • 5-FU
  • Oxaliplatin
  • Irinotecan
Drug: Capecitabine
Orally, for 10 days
Radiation: Short Course Radiation
Five or ten days
Procedure: Surgery
1-4 weeks after completion of capecitabine therapy

Primary Outcome Measures :
  1. Rate of Resection [ Time Frame: 2 years ]
    To determine the rate of R0 resection of patients with borderline-resectable adenocarcinoma of the head of the pancreas, along with borderline-resectable and resectable adenocarcinoma of the body and tail of the pancreas

Secondary Outcome Measures :
  1. Progression-Free Survival [ Time Frame: 2 years ]
    To determine the progression-free survival of patients who receive preoperative FOLFIRINOX and preoperative short-course radiation therapy

  2. Overall Survival [ Time Frame: 2 years ]
    To determine overall survival in patients treated with preoperative FOLFIRINOX and short course radiation therapy

  3. Toxicity rate [ Time Frame: 2 years ]
    To determine the frequency and severity of toxicities of FOLFIRINOX+short course radiation therapy in patients with pancreatic cancer

  4. Surgical Morbidity [ Time Frame: 2 years ]
    To determine the surgical morbidity in patients undergoing pancreaticoduodenectomy or distal pancreatectomy who received preoperative FOLFIRINOX and preoperative short course radiation therapy

  5. 30 Day Post-operative Mortality [ Time Frame: 2 years ]
    To determine 30 day post-operative mortality after pancreaticoduodenectomy or distal pancreatectomy in patients who receive preoperative FOLFIRINOX and short course radiation therapy

  6. Rate of Pathologic Downstaging [ Time Frame: 2 years ]
    To determine the rate of pathologic down-staging of FOLFIRINOX+short course radiation therapy for patients with pancreatic cancer

  7. Local Control Rates [ Time Frame: 2 years ]
    To determine local control rates with FOLFIRINOX+preoperative short course radiation therapy

  8. Correlation of Mutational Analysis Biomarkers [ Time Frame: 2 years ]
    To correlate mutational analysis biomarkers (SNaPSHOT assay) with response to treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cytologic or histologic proof pancreatic ductal carcinoma
  • Borderline resectable
  • Life expectancy of at least 3 months
  • ECOG Performance Status ≤ 1
  • Adequate organ and bone marrow function
  • No treatment of other invasive cancers within the last 5 years with greater than 5% risk of recurrence at the time of eligibility screening. Carcinoma in-situ and basal cell carcinoma/squamous cell carcinoma of the skin are allowed
  • > 4 weeks since major surgery, excluding laparoscopy

Exclusion Criteria:

  • Evidence of metastatic disease
  • Pregnant or breastfeeding
  • Other serious uncontrolled medical conditions
  • Prior chemotherapy, targeted/biologic therapy or radiation for treatment of the pancreatic tumor
  • Prior systemic fluoropyrimidine therapy
  • History of uncontrolled seizures, central nervous system disorders or psychiatric disability
  • Individuals on cimetidine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01591733

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Cancer Institute (NCI)
Principal Investigator: Theodore S Hong, M.D. Massachusetts General Hospital

Responsible Party: Theodore Sunki Hong, Principal Investigator, Massachusetts General Hospital Identifier: NCT01591733     History of Changes
Other Study ID Numbers: 11-328
First Posted: May 4, 2012    Key Record Dates
Last Update Posted: September 29, 2017
Last Verified: September 2017

Keywords provided by Theodore Sunki Hong, Massachusetts General Hospital:
Borderline resectable

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents